Literature DB >> 33685875

The Use of Primary Care Big Data in Understanding the Pharmacoepidemiology of COVID-19: A Consensus Statement From the COVID-19 Primary Care Database Consortium.

Hajira Dambha-Miller, Simon J Griffin, Duncan Young, Peter Watkinson, Pui San Tan, Ashley K Clift, Rupert A Payne, Carol Coupland, Jemma C Hopewell, Jonathan Mant, Richard M Martin, Julia Hippisley-Cox.   

Abstract

The use of big data containing millions of primary care medical records provides an opportunity for rapid research to help inform patient care and policy decisions during the first and subsequent waves of the coronavirus disease 2019 (COVID-19) pandemic. Routinely collected primary care data have previously been used for national pandemic surveillance, quantifying associations between exposures and outcomes, identifying high risk populations, and examining the effects of interventions at scale, but there is no consensus on how to effectively conduct or report these data for COVID-19 research. A COVID-19 primary care database consortium was established in April 2020 and its researchers have ongoing COVID-19 projects in overlapping data sets with over 40 million primary care records in the United Kingdom that are variously linked to public health, secondary care, and vital status records. This consensus agreement is aimed at facilitating transparency and rigor in methodological approaches, and consistency in defining and reporting cases, exposures, confounders, stratification variables, and outcomes in relation to the pharmacoepidemiology of COVID-19. This will facilitate comparison, validation, and meta-analyses of research during and after the pandemic.
© 2021 Annals of Family Medicine, Inc.

Entities:  

Keywords:  big data; coronavirus; epidemiology; primary health care

Mesh:

Year:  2021        PMID: 33685875      PMCID: PMC7939714          DOI: 10.1370/afm.2658

Source DB:  PubMed          Journal:  Ann Fam Med        ISSN: 1544-1709            Impact factor:   5.166


  18 in total

1.  Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.

Authors:  H Jick; S S Jick; L E Derby
Journal:  BMJ       Date:  1991-03-30

2.  Instruments for causal inference: an epidemiologist's dream?

Authors:  Miguel A Hernán; James M Robins
Journal:  Epidemiology       Date:  2006-07       Impact factor: 4.822

3.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

Review 4.  Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource.

Authors:  Tim Williams; Tjeerd van Staa; Shivani Puri; Susan Eaton
Journal:  Ther Adv Drug Saf       Date:  2012-04

5.  COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

Authors:  Ankit B Patel; Ashish Verma
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

6.  RCGP Research and Surveillance Centre: 50 years' surveillance of influenza, infections, and respiratory conditions.

Authors:  Simon de Lusignan; Ana Correa; Gillian E Smith; Ivelina Yonova; Richard Pebody; Filipa Ferreira; Alex J Elliot; Douglas Fleming
Journal:  Br J Gen Pract       Date:  2017-10       Impact factor: 5.386

7.  Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance.

Authors:  Jeremy A Rassen; M Alan Brookhart; Robert J Glynn; Murray A Mittleman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2009-04-05       Impact factor: 6.437

8.  Discovering drugs to treat coronavirus disease 2019 (COVID-19).

Authors:  Liying Dong; Shasha Hu; Jianjun Gao
Journal:  Drug Discov Ther       Date:  2020

9.  Data Resource Profile: Clinical Practice Research Datalink (CPRD).

Authors:  Emily Herrett; Arlene M Gallagher; Krishnan Bhaskaran; Harriet Forbes; Rohini Mathur; Tjeerd van Staa; Liam Smeeth
Journal:  Int J Epidemiol       Date:  2015-06-06       Impact factor: 7.196

10.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan
Journal:  PLoS Med       Date:  2015-10-06       Impact factor: 11.069

View more
  5 in total

1.  Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study.

Authors:  Hajira Dambha-Miller; William Hinton; Christopher R Wilcox; Mark Joy; Michael Feher; Simon de Lusignan
Journal:  Fam Pract       Date:  2022-05-17       Impact factor: 2.290

2.  Anxiety levels and solution-focused thinking skills of nurses and midwives working in primary care during the COVID-19 pandemic: A descriptive correlational study.

Authors:  Alime Selçuk Tosun; Nurcan Akgül Gündoğdu; Filiz Taş
Journal:  J Nurs Manag       Date:  2021-04-24       Impact factor: 4.680

3.  Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study.

Authors:  Christopher R Wilcox; Nazrul Islam; Hajira Dambha-Miller
Journal:  BMJ Open Respir Res       Date:  2021-03

4.  Primary care consultations for respiratory tract symptoms during the COVID-19 pandemic: a cohort study including 70,000 people in South West England.

Authors:  Hajira Dambha-Miller; Hilda O Hounkpatin; Jeffrey Morgan-Harrisskitt; Beth Stuart; Simon D S Fraser; Paul Roderick
Journal:  Fam Pract       Date:  2022-05-28       Impact factor: 2.290

5.  Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people.

Authors:  Hajira Dambha-Miller; William Hinton; Christopher R Wilcox; Agnieszka Lemanska; Mark Joy; Michael Feher; Beth Stuart; Simon de Lusignan; Julia Hippisley-Cox; Simon Griffin
Journal:  Fam Pract       Date:  2022-08-25       Impact factor: 2.290

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.